-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MRcQCTvhVpzx3c5fYmTGcZ1UGep8CpTos+ZmpXXy78fICuZZToVq5d/C3Qq1kcQb
 5l2f/ejQ4BHIvO7RPnu+0w==

<SEC-DOCUMENT>0001178913-09-000274.txt : 20090209
<SEC-HEADER>0001178913-09-000274.hdr.sgml : 20090209
<ACCEPTANCE-DATETIME>20090209070504
ACCESSION NUMBER:		0001178913-09-000274
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090209
FILED AS OF DATE:		20090209
DATE AS OF CHANGE:		20090209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		09578865

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk96353.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\edgar filing\Compugen Ltd\96353\a96353.eep              -->
     <!-- Control Number: 96353                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">


<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>FORM 6-K <BR>
SECURITIES AND
EXCHANGE COMMISSION </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Washington, D.C. 20549 </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Report of Foreign
Private Issuer </FONT></H1>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
<BR>for the month of February 2009</FONT></P>


<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>Compugen Ltd.</B></U> </FONT> <BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Translation of registrant's name in English)</FONT></P>


<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>72 Pinchas Rosen Street, Tel-Aviv 69512, Israel
</U><BR>(Address of principal executive offices) </FONT> </P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F. </FONT></P>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Form 20-F <FONT size="3" face="Wingdings">x
</font> Form 40-F <FONT size="3" face="Wingdings">o
</font></FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On February 9, 2009 Compugen Ltd.
(the &#147;Registrant&#148;) issued a Press Release, filed as Exhibit 1 to this Report on
Form 6-K, which is hereby incorporated by reference herein. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>SIGNATURE</U> </FONT> </H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized. </FONT></P>


<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Workstation" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compugen Ltd.<BR>(Registrant)<BR><BR>
<BR>By: /s/ Ms. Dikla Czaczkes Axselbard<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
Ms. Dikla Czaczkes Axselbard<BR> Chief Financial Officer<BR> Date: February 9, 2009</FONT></TD>
</TR>
</TABLE>
<BR>


<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\edgar filing\Compugen Ltd\96353\a96353.eep              -->
     <!-- Control Number: 96353                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Exhibit 1</U> </FONT> </H1>

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<IMG SRC="compugenb.jpg"></font></P>


<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>For Release </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Compugen
Appoints Dov Hershberg Chairman of the Board</FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>Martin
Gerstel Continues as President and Chief Executive Officer</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tel Aviv, Israel, February 9, 2009
&#150; Compugen Ltd. (NASDAQ: <U>CGEN</U>) announced today the appointment of Dov
Hershberg as chairman of the board, succeeding Martin Gerstel, who, as of the beginning of
this year, was appointed president and chief executive officer. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush Lv 0- TNR" FSL="Workstation" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Mr.
          Hershberg said, &#147;During the past few months, while serving as an advisor to
          the company, I have been exposed to Compugen&#146;s exceptionally talented
          scientific team and the Company&#146;s powerful discovery capabilities. I am
          delighted to join Compugen and help it realize its full potential to become the
          leading product discovery source for the drug and diagnostic industries.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Martin Gerstel, CEO, stated, &#147;I
look forward to working with Dov as our chairman. Currently, with ten validated predictive
discovery platforms and a growing number of initial product candidate discoveries, a much
larger portion of our efforts is being devoted to business development and
commercialization. These are areas, among others, where Dov brings to Compugen a wealth of
experience gained through his extensive management background in general, and specifically
in the field of collaborative arrangements, a result of his long term position as
executive director of the US/Israel Bi-National Industrial Research and Development
(&#147;BIRD&#148;) Foundation.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Dov Hershberg</B> is an executive
director and a board member of Powermat, a wireless electric power company that he
co-founded. He is also an advisory board member of the Merage Foundation. Mr. Hershberg
managed the BIRD Foundation for nine years, until mid 2006. <B><U>BIRD</U></B><U></U> is a
joint American Israeli foundation involved in the matching and financing of advanced
technology projects of Israeli and American companies. &nbsp;During Mr. Hershberg&#146;s
tenure, BIRD established ties with global leaders such as Applied Materials, Bayer,
General Electric, Guidant, Johnson &amp; Johnson, Motorola and Texas Instrument, as well
as with Israeli companies at various stages of development in virtually all areas of life
science and high tech. <BR><BR>Earlier in his career, Mr. Hershberg held various senior management
positions in product development, marketing and in sales, including eleven years with
Digital Equipment Corporation. He also founded, along with colleagues from Stanford
University, Molecular Applications Group, a biomedical research software company where he
served as CEO. Mr. Hershberg also worked as a mathematician in the Israeli Aircraft
Industry.&nbsp; Mr. Hershberg holds graduate degrees in mathematics from the Hebrew
University in Jerusalem, Israel and in applied mathematics and operations research from
Columbia University in New York City. </FONT></P>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>



<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About Compugen</B> <BR>Compugen is a leading drug and
diagnostic product candidate discovery company. Unlike traditional high throughput trial
and error experimental based discovery, Compugen&#146;s discovery efforts are based on
<I>in-silico</I> (by computer) prediction and selection utilizing a growing number of
field focused proprietary discovery platforms accurately modeling biological processes at
the molecular level. The resulting product candidates are then validated through <I>in
vitro</I> and <I>in vivo</I> experimental studies and out-licensed for further development
and commercialization under various forms of revenue sharing agreements. Compugen&#146;s
current collaborations include Biosite, Medarex, Inc., Merck &amp; Co., Inc.,
Ortho-Clinical Diagnostics (a Johnson &amp; Johnson company), Roche, Siemens Healthcare
Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an
affiliate, Evogene Ltd. <U>www.evogene.com</U> (TASE: EVGN.TA), to utilize certain of the
Company&#146;s <I>in-silico</I> predictive discovery capabilities in agricultural
biotechnology. For additional information about Compugen, please visit the Company&#146;s
corporate Web site at <U>www.cgen.com</U>. </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This press release may contain
&#147;forward-looking statements&#148; within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include words such as &#147;may,&#148;
&#147;expects,&#148; &#147;anticipates,&#148; &#147;believes,&#148; and
&#147;intends,&#148; and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks relating to the
development of new products; and the ability to implement technological improvements.
These and other factors are identified and more fully explained under the heading
&#147;Risk Factors&#148; in Compugen&#146;s annual reports filed with the Securities and
Exchange Commission. </FONT></P>

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Company contact:
</B><BR>Marjie Hadad
<BR>Global Media Liaison
<BR>Compugen Ltd.
<BR>Email: marjie@cgen.com
<BR>Tel: +972-54-536-5220 </FONT></P>


<p align=center>
<font size=2>2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugenb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 compugenb.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%$`U@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`;O7.WOV'K0!Q/Q+\>ZOX5U&"RTSX<>*O$YD0N\VE
M10^7%Z`M(ZY/TH`\;^(`@\:>(7UG7_@=\:FN&0($M-?DM8D4=ECANU0?ES0!
MB2^%O#B0,TGP-^.BHHRQ?Q==!0/<F^P!0!RGC>UM+;3H?^$'^!OQ%U.^ED"M
M'J/Q(GMT`[;=EZS,Q.,`"@#Z`_9S^#^A^'K6P\;ZUX.&F>,I;8QNMSKEWJQL
M48Y,<<MPS%6(QNV@#.1DB@#V*@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`/"OCC\3M+U3[?X//A_XOVB6ESL?5/"NG21&;8>0DP&=A/=<
M9QUQ0!Y>+GPX/^6W[57T^U7G^-`#EG\.$<2_M4_^!=Y_C0!Y_P#$B]UC5/[0
M\/\`_"J/VBO$WAZX'EG^T_%<\*W2?[<)C;C/8DT`;7[%?P9\":G\9[76;SX`
M^,O!TOAH+J-I>:]K+7$#SJV$`C,2Y93\X.>"H-`'W30`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$=U&TMM)&DK0LZE5D3&5)'49XXH`^4
M?&]W'X2\4W?AW6OVEOC+'?6+!9%M_"K7$?(##;)'9,K#!'()H`R/^$KT?_HY
MOXV_^$;/_P#(%`%;6=>\.ZEHUYIE[^TK\;IK:\A>&:(>#[A"Z,,$!A8@KD$C
M((H`^=SH7@@$JNC_`+3CA3C<@AP?<90'\P*`/3?V5/'?AGX1_$<ZM;>%?C[=
MVNIQK97?]NV4=Q;P1EU/G%8T\SY.3A>2">"<"@#]!].NH+VP@O;60207$:R1
MNO1E(R#0!-0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&;
MXNL=4U'P]=66BZT^C7TJ8AOT@28PMV.QQM;Z&@#YN^(WQ%O/`/BN?PSXP_:M
MATG5;94:2VG\'1YVL,J00A!!'<$]".H-`&%_POC0_P#H\>Q_\(Y/_C=`',>/
M_'G@_P`97%I+J'[;6HV+V@94_LC1'L@P."=^Q1NZ<9Z<T`>.M\5?#Z2.B_&W
M]HR3:Q&^+3[5D;'=3]JY![&@#TS]E3]HKPQX5^)EIIM[XZ^,7B*SUZ>.R:#Q
M+HUMY,,KL%23S5N&=`"><`Y!Z<4`??M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`'@7QI^*MO\`\)6MKX+_`&A?A-X;CLD,%[9:S)%<
M3B<,<\B==N!QM(SG-`'(?\+1\6?]'7_`K_P'C_\`DF@!5^*'BLG!_:O^!6.X
M^SQ]/_`F@#PKXG?'K5;SQK>,G[7[:=]G(MS%X?\`"TALV*\%T)<[@?[P.#0!
MH?`KQUXP^('Q8T/POH/[6_B76KFZN5DDLE\,O$)(D.^3<Y;"#:",GUH`_1"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`R=5\4^&=+OFLM2\
M1Z39W*`%H+B\CC=0>A*D@\T`>=_$CQQXODUI8_`7BOX5Q::JX9];U-VED;'.
M%CX`_$Y]J`.`9?&VXDS?LWY/)SO_`,*`.2^(WQ*7P&\,?B?7/V=+>6?E(;:S
MN+E\>I6-3@>YH`\Z\;_'2TUB&WCT'XK?!;PPT1)DEL_"D]PTOH#YT+``>PS[
MT`:7PB3XR_%&\FM/`'QL^'NK_9P3)/'X&1((SZ&1K4+N]LYH`^P?@=X'U+P=
MX3AB\2:Q9:[X@D&;O4K?2K>Q4YYV(D*+\@/3=DGK[``[B@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@#SGXC>,/B1IOB)[/P;X)\,ZSIZ(-UWJ/
MB;[$^_\`B41B"3@>I(^E`'DNI>$M4U'49]0U+]E[X,WMY=2&2:YN?$D<DDC'
MJ69K$DGW)H`KS>"6BA>67]E3X'QQQJ6=V\0P@*!U)/V#I0!X?\2]?T/4KR!?
M!.E?LJ^$H(AB9+BXM=2DF;_>DME"K[!<^_:@#'\-6/C/7M>M=%T#6?V6]1U.
M_D\JWM+/1K!Y97ZX`$'I0!],?L__`+-^K(PU/XR:-\,+D@,JZ)H?A"QCC]`T
MEQY>\]<[5"]!DGD4`?1/AO1=(\/:/#I6A:79:98VXQ':V4"PQ)]%4`"@"_0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?)4GPE>25Y)/V/-&
M9W8LS-XTC)8DY)/R^M`"?\*B_P"K.M$_\+./_P")H`JZW\([H:-=&Q_9`\,P
M7(B;RY;[Q>CP(<<,Z@`E1W&10!X[#X"\9R,L<?P7_9G>1B%"KJH)8]@!]KZF
M@#["_96^#6C?#_P[!KVI^!_!VA^,KV$I>OX;MG2&%"<B)&=W8XXW,",D>@%`
M'G/[57[;G@KX4^([KPEX:T:7Q;XALSLN!#.L5I:OG&QI`&+..ZJOMD&@#RC1
M_P#@H7XRT'Q:FG_$KX0+86QVR216DLL%U#$PR'"3##\<@94'U%`'U3\7_P!H
M/X<?#CX/Z;\1M:U-Y]-URWCN-*MK10UQ?[T#J$4D=B,DD`=S0!\GZ]_P4<\1
MR7KWF@?"*V31X9!&TM[?R.S$\X+)&%0D=N?QH`^B_P!D7]J;P;\<],U1(M.N
MO#NM:';_`&N]TZZD$J>3T,L<@`W*#@'(4@D<<YH`\'T__@HX9O%L6FS?"ZW@
MT][L0-?+K#R%8]^"X1;?+''(4=>E`&?XO_X*.ZM:^/98M#^&5JWA^VG,;)J%
MV\=[,@/7@;8F(_A(;'K0!I?&/_@HHECJEO:_#?P$+RU,4<TE[KDCQ;]P!*I$
MO.!R-Y;!P>,=0#V*X_:NT]?V)E^/4'A=GN!*EF=&FN?+#W!E$;A9=IRH!9@=
MO(&.*`/(/#G_``4>MKJPU634OA+=0W-K;^99V]GJ?G"9\\^8YB7RD`Y+8;Z4
M`=1^R-^W"_Q4^+MGX!\4>"[719]7+BQO;.],B;PI81NK*.2`?F!Z]J`*'Q[_
M`&^C\/OC)XB\$:9\,XM9@T&\-F+YM7,)F=0`_P`@A;&'W`<G.!0!U'[4/[8E
M_P#!N/P;;7/PZAU'4_$NC)JUU:G5#"++<<",'RF+\AADA>G2@#I?A=^U/I.J
M_LLWGQQ\>:"OA;2XKN2TM+*&Z^U2WK+PHCRB99FW`#H`I)(`.`#PG2?^"C>J
M7/C))KCX3^5X6A_X^S;7C37D*$X$@;8J<#^$@9/&X4`=-\%?V]-5^(WQE\/>
M`]/^$L5N-=U&.T^UG62QBB+9>39Y`R50,VW(Z8S0!WG[6W[9_@SX->*)/!^D
MZ'<>*_$MOL-S:P7"PP6N[^"27#'S,$':%/7DB@#R70_^"AOB#2/%<-C\1?A`
M^EV4Q21OL]S(ES#"V<2".5`)./=<X-`'LO[8G[6%A\%M#\&:GHGAJ+Q5#XSM
MI+VW;[<;4+`JQLK_`.K8G<)1C('0T`>/3_\`!1H-\/)]2A^&.S76O/LT-H;]
MWMHH]@;S)9?*7EB2%C4$G8Y)7Y=P!ZW^P+^U'>_'R\US0]>\,V^D:OHT:70D
ML9&:":%FV]&Y5@?<@@]L4`?2M`'SA\9O`?AK3/'=U+'\)?BEXG;4F:]EOM`U
ML+;B1V)9`KW494@]@N,$8]@#E/\`A&?#W_1N_P`<_P#P=Q__`"=0`V;PKX:F
MB>&7]G/XXO'(I5D;6HB&!X((^W=*`//_`(6?!^X'[0VC02_LI6&@>&UU,2PZ
MKJFJ$7,,*G<CM"+AE9QA<@;AF@#[@^).I7>C?#K7M7LHS)=:?I]Q<PJHR2Z1
MLR\#W%`'X[_LD6%CXM_:O\#P^*-4MXH+W7(KR[N+YP$G=6,VQB>"9'4)[EP.
M]`'U9^T5\6?V2/&OQWOX/$OP]\3>,/$,,R:3'>:4ZM#=NIVHL1$P#?,2`<<F
M@#R#_@J:'T?XZ:#X#LX'L]`\)^'+2VTJR8Y\F,@@Y/.X_*%SD_=H`O>//$O@
MOPS_`,$M?"/@?3-1TR\\1^+-5>^OX+:=&F@,<[L6D7[RX58DY_#(H`SOV&X=
M5\)?!KXS_%=T^SZ7;>&GT.WFD0[9[J9U.U#T.T`9]-ZT`<Y_P3:\+V?B;]KK
MPPFI1K)9Z(DVK2JPR,PQDH3_`,#*T`</XH^T_$W]IF]CA5/.\5>)##&%''[R
M?:/T-`'I/_!3?4]-D_:=G\.:,MNEAX0TNUTB-((@@4JFY@<>A;%`'7?M5'_A
M!O\`@GQ\&_AW'*L<^ONVOWD1^\05+(?I^^_2@#(_8L\2?#[P-^S7\9O$NOZS
MIR>(]2TPZ-IVF2RKY\JRQ.H*1GYF&]QDC@!><4`<U_P39T";5?VK_#^IXD6T
M\+PSZO=R!>$2.)@`3T&2P%`'G&EZG:>+/CY!K?BF_2RL]:\0"[U"[ER4B1Y]
M[D^P!_`4`>A?\%%?B#H_Q#_:AU?4_#6JP:IH6D6=OI6GW=N<QND:;GVG^)?-
M>3##@CD9%`'1?MLV&H>#O@!\"_AZ5EM[2'0IM8GC^8+)=3LI8GL2H)QW`<^M
M`$_P,\>?#7P%^P!\1M/DU.RF\=^-IVTQ=."DW'D[556/&`BJTK@YQGCK@4`5
M?^"7&BSW/[15]XG@LQ<R>$=`O=0@4C(\\IY:#TYW-0!Y7\"M%U_XG?M#:+8Q
M>)X=,U[6]0>\&M7RAUCN`KS>8PZ$EEX]R*`/5?C5X'T/Q9\6)-.^('[5VBZ_
MXJM672@5T*_NOFW';"LD,11L,Y'!."2.H(H`H_\`!1R7^Q_BUX8^&BWYNT^&
M_A+3=#DDVE0TJPAV8#W5HS^G:@#J/CY:Z;X&_P""9_PI\,1VD=OJOC34I-=N
M"8_GE1%<[R>N0LT`'L:`/6/^")7AB2/0/'OC211Y=U=6VEP-GH8D:20?^1HO
MRH`^[:`.<^)W@RQ\;^'/['O=6UW2D$BRBYT349;*<$=O,C(.#GD'B@#SW_AG
M#P__`-%)^+/_`(6%Y_\`%4`'_#.'A_\`Z*3\6?\`PL+S_P"*H`CTG]F'P!:?
M$'0_&MYKOC;6=8\.2^=83ZQK\]WY)ZD#>3\I[CO0![/)&KAE<!E88*D<8H`^
M4?BA^P!\(?$WB&YU71=2UGPW]KF,SVEFRO`I)RP16'RCT&<#M0!V/[/G['GP
M?^$_BF#Q/I]E>ZSK5FV^UN]5E#BV;D;D0`*&YZD$CJ,&@#H/VG/V;OAQ\<;>
MWF\4VMS;:O91^5;:K92;)HTR3L(/#+DYP1QV(H`\9\'_`/!.OX5Z;J8N-<\4
M>(M7A4@_9PR0!L=B5&<?3%`'N_Q'^`_@3Q5\!H_A!;6TV@>&(3&8[?2F",H1
MMV,MDG)Y).2222<F@#D/@)^R1\._A)JNMZEX:U+6I+O6],DTMY;J5&:&-R"Q
M0A1AN!S0!@?"O]AOX3^`_B)HGC'3=3\07-YH5TEY!%<SH8S(ARI("CH<'\*`
M(_B3^PQ\+O&_CW6/%VLZ_P")C?ZU=/=3A+A`H9CT'R].U`'RE_P5HUNS;]H7
M2?!NGLJV7@_1(+.-`1\A;YL?4*%H`]/_`&=_V)?`_P`3_P!F+P9XJU?4=3T+
M7M1@DNI[FS(83Q/(3'N5N`0F,$8X-`'U?^SA\!?A]\%?"EUHOA33Y)9-1Q]N
MOKUO,FNL`@!CT"@$_*!CF@#Q]O\`@G[\&&\>MKC7VO?V8TIE_L43J(AEL[=^
M-VSMC.<=Z`)O$7[`_P`&]6\576MM>ZY:_:KDW!L[:6-((P6R$5=O"@<?2@#@
M/^"F'Q(\`:-XDTOX7_$7X27VL:?IUHEWH^KVNH_99%#*$<(=IX!4!E.0=JG'
M`H`^5OBOXF^`"?!BVT?X8^"M;M/$VIW,<VI:AKDPF-I$F3Y4##&=S;23M!PI
M'>@#[3_X)*?!W5_`?PVUCQIXITJXT[4_%<B);VMTFR1+5`2K,IY&YF)P>P%`
M%GXH_P#!/WX2>)O$MQJV@ZIJWAB.ZD,C6%GLDMXR>HC5A\HSVS@=L"@#L/V?
MOV-?A!\*?%=KXHLX-0UK6;')M[C4Y0Z0L?XUC``##L3G%`&9\7_V)/AG\1OB
M/K7C77]?\2C4M;G,\WE3H$3@*JJ-O0*%`SZ4`='\>?V5O`?Q7TSPKIFN:KK=
MI8^#[`V%A;64JJH4A`6.5/S$1H/PH`[;]FWX1>&O@I\.CX.\+37<UFUU)>/+
M=L&D=WP#D@`<!0/PH`[^@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^1_VD_\`
MDM6N?2'_`-%B@#Z5^$'_`"2SP]_V#X?_`$`4`='0`4`%`'S?_P`%.?\`DWZ+
J_K_7_P!!-`'P?_P3B_Y._P##7_;;_P!!-`'[`4`%`!0`4`%`!0`4`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
